Reported Late Monday Feb.27, South Korea's GC Biopharma, Announced Today That It Has Signed An Asset Purchase Agreement With Catalyst Biosciences To Acquire 3 Programs Related To The Orphan Hematology Disorders; No Financial Terms Disclosed
Reported Late Monday Feb.27, South Korea's GC Biopharma, Announced Today That It Has Signed An Asset Purchase Agreement With Catalyst Biosciences To Acquire 3 Programs Related To The Orphan Hematology Disorders; No Financial Terms Disclosed
GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ:CBIO) to acquire 3 programs related to the orphan hematology disorders.
韓國領先的生物製藥產品供應商 GC 生物製藥公司 (006280.KS) 今天宣佈，已與催化劑生物科學 (NASDAQ: CBIO) 簽署資產購買協定，收購 3 個與孤兒血液疾病相關的計劃。
This agreement will bring to GC Biopharma 3 programs, including "Marzeptacog alfa (MarzAA)", an engineered factor VIIa which is ready for Phase 3 clinical stage development.
該協議將帶給 GC 生物製藥 3 項計劃，包括「馬爾澤普塔克阿爾法（MarzaA）」，這是一種工程因子 ViIa，已準備好用於 3 期臨床階段開發。
In its previous clinical development trials, "MarzAA" demonstrated efficacy and safety as a treatment for rare bleeding disorders. More significantly, "MarzAA", unlike majority of existing therapeutics, is delivered by subcutaneous injection, making it more convenient to administer and less burdensome for the patients, who require life-long treatment.
在先前的臨床開發試驗中，「Marzaa」證明了治療罕見出血性疾病的療效和安全性。更重要的是，與大多數現有治療藥物不同的是，「Marzaa」是通過皮下注射提供的，從而使需要終身治療的患者更方便地管理並減輕負擔。
It is GC Biopharma's plan to continue development of the asset in pursuit of launching a first-in-class novel drug that will pave the way for the company to make inroads into the global markets, including the US and other advanced markets.
GC Bioharma 計劃繼續開發該資產，以追求推出一種一流的新型藥物，該藥物將為該公司進入全球市場（包括美國和其他先進市場）鋪平道路。
Since its founding, GC Biopharma has worked on providing better therapeutic options for hemophilia, one of the most well-known rare bleeding disorders. "Green Mono", a plasma-derived FVIII drug, and "GreenGene F", a recombinant FVIII drug are hemophilia drugs exclusively developed by the company. GC Biopharma is keen to develop new drugs for various orphan disorders not only through its in-house R&D capabilities, but also through leveraging its strength in managing external partnerships.
自成立以來，GC Bioharma 一直致力於為血友病提供更好的治療選擇，血友病是最知名的罕見出血性疾病之一。「綠色單聲道」是一種等離子體衍生的 FVIII 藥物和「綠色基因 F」，重組 FVIII 藥物是該公司獨家開發的血友病藥物。GC Bioharma 熱衷於開發用於各種孤兒疾病的新藥，不僅通過其內部研發能力，而且還通過利用其實力來管理外部合作夥伴關係。
Nassim Usman, Ph.D., President and CEO of Catalyst Biosciences, said, "We are pleased that GC Biopharma has purchased our hemophilia assets and will continue their clinical development to potentially bring new transformative treatments for several bleeding disorders".
Nassim Usman 博士，催化劑生物科學總裁兼首席執行官表示：「我們很高興 GC Bioharma 購買了我們的血友病資產，並將繼續其臨床開發，以潛在為幾種出血疾病帶來新的變革性治療方法」。
"We will extend our continuous global endeavour to improve therapeutic treatments for patients suffering from many orphan disorders, including rare bleeding disorders", said Eun-Chul Huh, Ph.D., President of GC Biopharma.
GC Bioharma 總裁 Eun-Chul Hh 博士表示：「我們將繼續努力改善患有許多孤兒疾病（包括罕見出血性疾病）患者的治療方法。」
RM Global Partners LLC acted as GC Biopharma's advisors for this transaction.
RM 全球合作夥伴有限責任公司擔任 GC 生物製藥這項交易的顧問。